Treatment Study for Patients with BRAF V600E Mutation Positive Craniopharyngioma

Clinical Trial Title

Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas.

Clinical Trial Protocol Description:

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have local diagnosis of papillary craniopharyngioma and have tissue slides available for submission to central pathology review.
  • Have histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC.
  • Are at least 18 years of age.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Joo Yeon Nam, MD

Contact Information

Rush Cancer Center Clinical Trials Office